Studies were designed to examine the effect of a selective endothelinA (ETA) receptor antagonist, BQ123, on severe postischemic acute renal failure (ARF) in Sprague-Dawley rats. Severe ARF was induced in uninephectomized, chronically instrumented rats by 45-min renal artery occlusion. BQ123 (0.1 mg/kg. min) or vehicle was infused intravenously for 3 h on the day after ischemia. Measurements before infusion (24 h control) showed a 98% decrease in glomerular filtration rate (GFR), increase in fractional excretion of sodium from 0.6 to 39%, and in plasma K+ from 4.3 to 6.5 mEq/liter. All vehicletreated rats died in 4 d because of continuous deterioration of renal function, resulting in an increase of plasma K+ to fatal levels (> 8 mEq/liter). Infusion of BQ123 significantly improved survival rate (75%) by markedly improving tubular reabsorption of Na' and moderately increasing GFR and K+ excretion. Plasma K+ returned to basal levels by the 5th d after ischemia. Improved tubular function was followed by gradual recovery in GFR and urinary concentrating mechanism.
Introduction Eridothelin (ET)
I (a 2 1-amino acid peptide), initially isolated from the endothelial cells, is the most potent vasoconstrictor known to date ( 1) . Endothelin mediates its responses by binding to specific cell surface receptors. Based on the binding profiles and pharmacology of ET peptides, two types of ET receptors (ETA and ETB) have been identified, cloned, and sequenced (2, 3) . There is accumulating evidence in the literature regarding the possible role ofendothelin in the pathogenesis ofacute renal failure (ARF) after ischemia. Some ofthe evidence is circumstantial, such as increased plasma level of ET-1 in patients with ARF (4), elevated tissue level of ET in postischemic kidney (5) , or the time-dependent increase in the affinity of renal ET receptors during reperfusion after ischemia (6) . More direct evidence has been obtained from studies with ET antibody (5, 7, 8) or receptor antagonist (9) . To date, the results indicate that ischemia-induced ARF is attenuated by the infusion of ET antibody or receptor antagonist during ischemia or the early phase of reperfusion.
The profile of changes in renal tissue and plasma levels of ET and in the affinity ofrenal ET receptors during the postischemic period suggested to us that ET may also be an important factor during the maintenance phase ofARF. The current studies were designed to assess such a possible role. A selective ETA receptor antagonist, BQ123 (10) , was infused 24 h after ischemia in rats with moderate and severe ARF. The effect of the blocker on normal renal function was also evaluated in rats with intact kidneys. The results show that blockade of ETA receptor 24 h after ischemia effectively reverses severe renal damage. Furthermore, they also indicate that the acute effect of ETA receptor blockade involves improved tubular reabsorption of Na', suggesting that ET may be a significant factor in the genesis of ARF by its contribution to renal tubular dysfunction. For the occlusion ofthe renal artery, the rats were anesthetized with pentobarbital (40 mg/kg i.v.), and the left renal artery was exposed though a small flank incision and occluded with a nontraumatic clamp. Body temperature was maintained at 37°C throughout the occlusion. Occlusion lasted 30 min for the moderate ARF group and 45 min for the severe ARF group. The incision was closed after the removal ofthe clamp, and the rats were returned to their metabolic cage to recover.
Methods

Animal preparation
Experimental groups
Prolonged effects of BQ123 treatment. The experiments were performed in the rats exposed to 45-min renal ischemia (severe ARF). They were housed in metabolic cages before ischemia, for 7 d and again on the 14th d after ischemia. Starting at 24 h after ischemia, vehicle or BQ 123 was infused for 3 h via the intravenous catheter at a rate of 0.1 mg/kg. min, a dose that effectively (50%) blocks the pressor response to a maximum dose of ET-1. Urine was collected under oil, and daily blood samples (500 jA) were drawn via the arterial line. GFR in this group was calculated from the clearance of endogenous creatinine.
Acute effects ofBQ123 treatment. Renal clearance studies were performed in conscious rats with moderate ARF (30-min occlusion). On the day after ischemia, the rats were placed in an experimental cage and set up for renal clearance study as previously described ( 11) . Briefly, throughout the experiment, isotonic saline containing 2.5% inulin (IsoTex Diagnostics, Friendswood, TX) and 0.25% p-aminohippurate (PAH) (Merck Sharp & Dohme, West Point, PA) was infused intravenously at a rate of 20 gl/min. Urine was collected from the indwelling bladder cannula. 1-h equilibration was followed by two 30-min urine collections (control). Then vehicle or BQ123 (0.1 mg/kg min i.v.) was infused for 3 h. Six additional 30-min urine collections were performed. A blood sample (300 ul) was drawn at every hour from the arterial line. The plasma was separated, and the cells were resuspended in saline and returned to the rats.
Renal effects of BQ123 in normal rats. The effects of BQ123 on normal renal function were evaluated in two groups ofconscious Sprague-Dawley rats with intact kidneys. Total sodium infusion was 1 ;sEq/ min -100 g in the first group (n = 5), 3 gEq/min * 100 g body wt (n = 6) in the second group of rats during the renal clearance protocol. Inulin and PAH concentrations ofthe infusate were 10% and 1%, respectively. After 1-h equilibration and two 30-min control urine collections, BQ123 was infused at 0.1 mg/kg min i.v., the same rate as in the rats with ARF. Urine collection was resumed 20 min later and two more 30-min collections were obtained. Blood samples were taken at the midpoint of each urine collection.
Analyses
Urinary and plasma concentrations of inulin and PAH were determined by the anthrone method ( 12) and by the method of Smith et al. ( 13), respectively. Creatinine, blood urea nitrogen (BUN), and electrolytes were measured using a Synchon AS8 clinical analyzer, osmolality by a model 2430 Precision osmometer. Clearance and excretion data are given as absolute values, expressed per hour for the prolonged study (group 1), per minute for the acute studies (groups 2 and 3). Fractional excretion of electrolytes was calculated as percent of creatinine or inulin clearance.
Values are expressed as means±SEM. ANOVA, Tukey compromise, Fisher's exact (to compare survival), and Wilcoxon (nonparametric) tests were used, and the differences were considered significant at P<0.05. 
Results
Prolonged effects ofBQ123 treatment: severe ARE. The pertinent data are presented in Table I (only for the BQ 123-treated group) and in Figs. 1 and 2 for both vehicle and BQ123-treated groups. In unilaterally nephectomized, chonically catheterized rats, 45-min occlusion of the renal artery leads to severe ARF, with a mortality rate of 95-100% in 3-4 d after ischemia. As illustrated in Fig. 1 A, all vehicle-treated rats in this study died within 3 d after treatment. In contrast, all rats treated with BQ123 survived for 4 d and 75% fully recovered. GFR was barely detectable (1.8 ml/h, 1.5% of basal) on the day after ischemia (24 h control; Table I , Fig. 1 B) . BQ123 treatment elicited gradual improvement in GFR with a significant increase by the first day after treatment. However, GFR was still 75% below control level on the 6th d, but fully recovered in 2 wk. The time course ofchanges in plasma creatinine (Fig. 1 C) and BUN (not shown) also indicate a slow improvement in renal hemodynamic function. (Fig. 2 B) , resulting in a significant increase in the level of plasma K+ (Fig. 3 C) . These changes in tubular function were irreversible in the vehicle-treated rats, resulting in a fatal concentration ofplasma K+ (> 8 mEq/liter) by the 2nd or 3rd d after ischemia (Table I) .
BQ123 treatment elicited a rapid improvement in tubular function. Na' reabsorption improved markedly,-FENa+ decreased significantly during the 1st d after treatment (Fig. 2 A) .
The improvement continued at a fast rate during the next few days, in contrast to the slow recovery in GFR. Concomitant with the twofold increase in GFR, there was a similar increase in K+ excretion on the first day after BQ123 treatment (Table   I , Fig. 2 B) . The increase in plasma K+ was reversed and returned to basal level by the 4th d after treatment (Fig. 2 C) . All other measured parameters of renal function returned to normal by the end of 2 wk after ischemia. Acute effects ofBQ123 treatment: moderate ARF. Technical difficulties (too low GFR) prevented us from performing acute renal clearance studies in the severe ARF model. Therefore, these studies were carried out in rats with moderate ARF. As the results in Fig. 3 show, GFR and renal blood flow (RBF) were decreased by 90 and 75% from basal values, respectively, at 24 h after 30 min ischemia. GFR increased gradually (not significantly) during the 3-h infusion of BQ123, and RBF remained unchanged (Fig. 3 A and B) . In contrast, the effect of BQ123 on the excretion of electrolytes was acute and highly significant. FENa+ decreased from 7.2±0.8 to 1.5±0.4% during the 3-h infusion (Fig. 3 C) and K+ excretion (absolute) increased from 1.29±0.03 to 3.65±0.1 gEq/min (not shown). Renal effects of BQ123 in normal rats. When infused in conscious rats with intact kidneys, BQ 123 infusion resulted in moderate (not significant) lowering of blood pressure from 1 13±4 to 106±3 mmHg, but had no effect on renal blood flow, which averaged 21.8±1.3 ml/min. As shown in Fig. 4 , the ETA receptor antagonist lowered urine flow in both the low (Fig. 4  A) and the high sodium groups (Fig. 4 B) without changing GFR. Decrease in osmolal excretion alone accounted for the drop in urine flow. As shown by the changes in the fractional excretion of electrolytes, BQ123 significantly increased Na' reabsorption and also decreased K+ excretion in both groups.
Discussion
The results of these studies show that in rats with severe ARF, blockade of the ETA receptor subtype with a selective antago- nist, BQ 123, initiated a regeneration process that normally occurs in moderate ARF (for review see reference 14) . The data also indicate that BQ 123 effected an immediate improvement in Na' reabsorption and K+ excretion, which led to the reversal in the increase and eventual lowering of plasma K+. The initial improvement in tubular function was followed by a slow but complete recovery in GFR and urinary concentrating mechanism.
A role for ET in the pathogenesis ofischemia-induced ARF has been proposed and supported by various experimental evidence. For example, progressive increase in ET-1 levels in plasma (4), renal tissue (5) , and cultured kidney cell lines ( 15) after ischemia has been observed. The measured increase in renal tissue ET-1 levels could result from increased synthesis, decreased degradation, or both. We recently reported that ET receptor affinity increases in the renal cortex during the first 24-h postischemic period parallel with functional impairment (6) . Results from earlier work with ET antibodies (5) and a recent study with BQ 123 (9) suggested an involvement for ET during the early phase of ARF. We also found in preliminary studies that when infused for 2 h starting at 30 tubular function after BQ 123 administration or the cascade of events leading to full recovery cannot be inferred from our results at this time. First of all, there is scarce information on the two ET receptor subtypes' role in the kidney, and the available evidence is conflicting. On the one hand, results from radioligand binding ( 17) , as well as mRNA measurements ( 18), suggest that ETA receptors are located primarily on vascular smooth muscle cells and ETB receptors are found on the tubular epithelial cells. In contrast, there is emerging evidence from whole animal studies with selective agonists and antagonists of ETA and ETB receptors, indicating that at least in the rat, renal vasoconstriction is not mediated by the ETA receptor ( 19, 20) . Early attempts to assess the tubular effects ofendothelin mostly involved infusion of exogenous ET-1. Results of a current study by Uzuner and Banks in anesthetized rats indicate that the ET-1-induced increase in sodium excretion is mediated by an increase in blood pressure (21 ) . We have made similar observations in the conscious rats (unpublished observations), leading us to conclude that selective antagonists to the ET receptor subtypes will have to be used to elucidate the tubular effects of endogenous ET. Our results from the clearance studies in conscious rats with intact kidneys (Fig. 4) (24) . It remains to be determined how these pathways are affected after ETA receptor blockade. Nevertheless, it is evident from our functional data that ET contributed significantly to tubular epithelial malfunction after ischemia. In the vehicle-treated rats, impaired tubular function and reduced GFR led to elevation of plasma K+ to fatal levels within 2-3 d. Infusion of BQ123 reversed the deteriorating tubular function and initiated a recovery process by increasing Na' reabsorption, GFR, and urinary excretion of K+. The data listed in Table I clearly show that the increase in K+ excretion was caused by increased filtration; its fractional excretion actually decreased. Extrapolation from these results would suggest that increased Na' -K+ -ATPase activity after ETA receptor blockade may well be the triggering mechanism of increased Na+ reabsorption. Improved potassium excretion may contribute to the gradual decrease in extracellular K+ level, one of the putative stimulants of growth factor release by the tubular epithelial cells (25, 26) . However, other factors may be more important in bringing on improvement in the internal K+ balance; e.g., decrease in cell death or moderation of metabolic acidosis. Further studies are needed to characterize these, as well as the specific morphologic changes and biochemical pathways during the regenerative process, leading to eventual restoration of GFR and urinary concentrating mechanism.
From the observations presented here, we conclude that ET is an important factor in the kidney during the prolonged reperfusion phase after ischemia and contributes significantly to the deterioration of the tubular epithelial cell function. This effect is mediated by the ETA receptor subtype, whose major role under normal physiologic conditions in the rat kidney appears to be controlling sodium reabsorption. Severe ischemiainduced ARF is reversed by the selective ETA receptor antagonist BQ 123 by significantly improving the tubular reabsorption of Na', and moderately increasing GFR and K+ excretion. A possible role for the ETB receptor subtype cannot be addressed at this time, because of the lack of ETB-selective antagonist. These findings may be ofclinical importance, providing a possible therapeutic approach in the treatment ofpostischemic ARF during the maintenance phase.
